NewsBite

Michael Smith

This Month

St Vincent’s is the nation’s largest not-for-profit health and aged care provider.

Hospitals heading for a ‘fiscal cliff’ without funding fix

Soaring inflation and wages have prompted Catholic Health Australia to warn the survival of some hospitals cannot be guaranteed more than three months out.

Barry Regan, chief executive of Saluda Medical, says the company will list on the ASX on Friday.

Saluda Medical shares sink in worst ASX debut in decades

Former Cochlear boss Catherine Livingstone sits on the board of the US-based company which lost more than 50 pct of its value on the first day of trading.

The Australian Medical Association (AMA) says health insurance premiums have doubled since 2008.

Doctors concerned Australians are dumping gold-tier health policies

More Australians are abandoning top-level private health insurance as premiums have doubled since 2008.

Police are investigating yet another tobacco shop fire in Glenroy on October 7.

How the tobacco tax backfired and fuelled a black-market boom

After decades of declining smoking rates, doctors fear the black-market tobacco is creating a new smoking boom, as the government loses a key source of revenue.

After decades of deal-making, Dennis Bastas landed his biggest transaction so far in August.

Dennis Bastas’ rise from aspiring car designer to $5b pharma king

The son of Greek immigrants signed a mega-deal this year for his pharmaceutical and beauty empire that propelled him to the upper echelons of the Rich List.

Advertisement
Barry Regan, chief executive of Saluda Medical, says the company will list on the ASX on Friday.

Saluda Medical set for $775m ASX debut

With links to Cochlear, the US-based med-tech company has global ambitions for its spinal cord stimulator technology.

NDIS workers submit invoices on serviettes in a system gone ‘wild’

A major NDIS plan management provider says the scheme is bogged down by red tape and needs an urgent overhaul of the payments system.

November

Stephen Anthony says a digital payments platform would make the NDIS more accountable.

Call for NDIS pricing fix to stop overpayments, fraud

Fraud and overpayment risks in the $50 billion scheme can be reduced if a proposed payment system overhaul is implemented, experts say.

The pharmacist from Fitzroy who amassed a $7b fortune with Chemist Warehouse

The pharmacists who’ve been made rich by following Chemist Warehouse’s Mario Verrocchi call him The Godfather. He’s told them to get back to work.

NDIS Minister Jenny McAllister says new laws will help protect the scheme’s participants from dodgy operators.

NDIS providers face $16.5m fines, jail under crackdown

New laws will include harsher penalties and jail time for dodgy providers and stronger powers for regulators to tackle abuse.

Chairman David Thodey faced unhappy shareholders at the company’s annual meeting on Tuesday.

Ramsay Health earnings recover in first quarter, Sante decision close

Australia’s largest private hospital operator says EBIT grew 5.8 per cent in the first quarter, but “not where we want them to be”.

The fertility group has suffered reputational damage caused by two embryo mix-ups.

Monash IVF rejects $300m takeover bid from Genesis Capital as too low

Shares in the fertility group have fallen more than 40 per cent since mistakes were disclosed earlier this year, prompting the PE-led consortium to swoop.

Mayne Pharma’s Adelaide factory is at the centre of Cosette’s $672 million bid for the company.

Chalmers kills $672m Mayne takeover on national interest grounds

The drug manufacturer’s shares plunged 23 per cent on the treasurer’s announcement before being placed in a trading halt. Shareholders are furious.

Mayne Pharma’s Adelaide factory is at the centre of Cosette’s $672 million bid for the company.

Mayne shares rally on bid approval hopes as FIRB delays its ruling

In a last-minute decision, the takeovers tribunal has ruled that US healthcare giant Cosette must run Mayne Pharma’s Adelaide factory as part of its bid.

The embattled fertility group says it will bounce back from the reputational damage from two embryo mix ups.

Monash IVF says market share, patients down since embryo mix-ups

Stiff competition and pricing pressure in Victoria has hurt the fertility group’s performance so far this fiscal year.

Advertisement
US pharma want Donald Trump to take “urgent action” on the way medicines are subsidised in Australia.

US pharma ramps up attack on Australia’s ‘discriminatory’ drug pricing

The lobby group representing US drug giants says Australia’s drug pricing policies are harming American innovation and jobs.

cochlear factory

‘Japan is safer’: Tokyo’s warning on Cochlear’s China factory

The hearing implant giant says it has no plans to invest in manufacturing in the United States despite Trump’s tariff threats.

CSL chief executive Paul McKenzie says the company will create more American jobs.

CSL plans $2.3b US manufacturing plant as Trump tariffs loom

The global biotech is promising to create American jobs but has not said where its new plasma therapy manufacturing site will be located.

Health Minister Mark Butler faces challenges reducing NDIS growth to 8 pct.

Thousands still flocking to NDIS as costs soar

Almost 14,000 children joined the scheme between July and September this year, more than 66 per cent of total new participants.

Nadia Badawi at Westmead Hospital, where she was in a position to gather data on babies born with cerebral palsy and set up early detection units.

The Australian doctor leading a global fight against cerebral palsy

Australia has one of the lowest rates of cerebral palsy in the world, which Nadia Badawi wants to replicate in other countries.

Original URL: https://www.afr.com/by/michael-smith-j7geb